Lexicon Pharmaceuticals (NASDAQ:LXRX) Announces Quarterly Earnings Results

Lexicon Pharmaceuticals (NASDAQ:LXRX) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02, Zacks reports. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The company had revenue of $26.55 million for the quarter, compared to analyst estimates of $6.48 million.

Lexicon Pharmaceuticals Stock Performance

Shares of NASDAQ:LXRX opened at $0.37 on Friday. The company has a current ratio of 7.45, a quick ratio of 7.43 and a debt-to-equity ratio of 0.56. Lexicon Pharmaceuticals has a 1-year low of $0.28 and a 1-year high of $2.83. The stock has a market capitalization of $90.54 million, a P/E ratio of -0.49 and a beta of 1.04. The business has a 50-day moving average price of $0.73 and a two-hundred day moving average price of $1.15.

Analyst Upgrades and Downgrades

LXRX has been the topic of several research reports. Leerink Partners reiterated a “market perform” rating and set a $1.00 price target (down previously from $2.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday. Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday. HC Wainwright reissued a “buy” rating and issued a $4.00 price target on shares of Lexicon Pharmaceuticals in a report on Monday. Finally, Leerink Partnrs cut shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $2.50.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

A hedge fund recently raised its stake in Lexicon Pharmaceuticals stock. Bank of America Corp DE boosted its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 27.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 136,407 shares of the biopharmaceutical company’s stock after buying an additional 29,319 shares during the period. Bank of America Corp DE owned approximately 0.06% of Lexicon Pharmaceuticals worth $101,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.